格隆汇8月1日｜东方证券研报指出，洽洽食品预计上半年归母净利润为8,000–9,750万元，同比下降约 71–76%，主因是原料采购价格大幅上涨带动毛利率下行。公司25Q1收入同比下降13.7%，反映出主力 品类动销放缓、渠道去库存延续。该行判断，公司当前主动压缩利润释放节奏，在保证终端投放与品牌 维护的前提下进行结构优化，为后续增长修复创造空间。考虑到原料端成本上行叠加主力品类出货节奏 偏慢，公司上半年利润显著下滑，我们修正了瓜子与坚果等核心品类的销售增速、新品导入的放量节奏 及毛利率改善幅度等关键假设。据此调整公司盈利预测，预计公司2025–2027年EPS分别为 1.25/1.42/1.67元（前次预测2025/2026年EPS为2.42/2.75元）。考虑公司在渠道端持续推进精耕、海外市 场具备中长期潜力，参考当前可比公司估值水平，给予公司2025年21倍PE，对应目标价26.25元，维 持"买入"评级。 ...

智通财经APP获悉，东方证券发布研报称，海外数据中心相关CAPEX自24H1以来维系高增，且持续上 修后续预期。2025Q2微软、谷歌、meta的CAPEX在原有基础上均高于预期，AI需求激活海外资本支出 投入上行。AI需求迭代，激活AIDC电源技术不断演进，高效率、高密度、高稳定性电源重要性将持续 提升。随着中国内地企业技术持续迭代，缩小与台资与外资企业的技术代差，并通过ODM/GPU企业认 证/CSP企业认证等等方式逐步接入生态，中国内地AI电源公司亦有望充分受益海外AICAPEX景气浪 潮。 AIDC电源：海外AIDC投资景气度提升，相关电源产业链环节有望受益，建议关注麦格米特 (002851.SZ)、禾望电气(603063.SH)、新雷能(300593.SZ)、通合科技(300491.SZ)、欧陆通(300870.SZ)、 中恒电气(002364.SZ)等。 AIDC电力配套：数据中心电力投建过程中，存在重要的配电需求，建议关注金盘科技(688676.SH)、明 阳电气(301291.SZ)、威腾电气(688226.SH)、良信股份(002706.SZ)等。 东方证券主要观点如下： 风险提示 海外CS ...

Group 1 - The core viewpoint of the article highlights that Aide Biology's semi-annual report shows strong performance, demonstrating growth resilience despite challenges in the IVD industry [1] - The IVD industry is currently facing pressure on growth due to medical insurance cost control and extended hospital payment cycles [1] - Starting from 2025, the value-added tax rate on the company's reagent sales will increase from 3% to 13% [1] Group 2 - Aide Biology is a leader in tumor drug companion diagnostics, with a comprehensive range of products and multiple exclusive approvals, contributing to stable revenue performance [1] - The main revenue source is testing reagents, which generated revenue of 480 million yuan, a year-on-year increase of 7.9%, accounting for 83.4% of total revenue, with a gross margin of 90.7% [1] - Technical services and testing services generated revenues of 60 million yuan (down 5.0% year-on-year) and 30 million yuan (up 0.9% year-on-year), respectively [1] Group 3 - The company's overseas business showed stable performance, achieving revenue of 110 million yuan in the first half of 2025, a year-on-year increase of 3.7%, accounting for 18.3% of total revenue [1] - Based on the average valuation of comparable companies for 2025, the company is given a target price of 26.56 yuan, corresponding to a price-to-earnings ratio of 32 times [1] - The rating for the company is maintained at "Buy" [1]

东方证券研报指出，AI本地化部署需求兴起，深信服有望充分受益。公司对一朵云解决方案面向AI进 行全新升级，为用户打造更匹配大模型场景的智算承载、应用构建的AI平台。其中，AICP高性能算力 平台在多实例、高并发场景下，性能相比传统Ollama架构方案提升5-10倍，可广泛适配包括DeepSeek在 内的最新大模型。此外，公司的AI应用创新平台，助力用户快速构建大模型应用，让AI应用的开发运 营更加简单。公司的全栈化能力为大模型本地化部署提供了"高性能、高安全、高价值"的一站式解决方 案，随着国产化替代与AI需求的持续增长，公司有望在各行业智能化转型的过程中不断受益。根据可 比公司25年的PS水平，给予公司25年6.10倍PS，对应目标价为119.00元，维持"买入"评级。 ...

东方证券研报指出，近期，朗新集团正式向全球首发自主研发的"朗新九功AI能源大模型"（简称"朗新 九功"），该模型数据智能体在BIRD-Bench国际评测基准中斩获双榜冠军。朗新九功模型深度融合 了"时序预测"与"AI智能体"双引擎技术，基于对中国能源市场全场景的数据沉淀与实践验证，打造出能 够解决能源行业复杂核心问题的垂直大模型。在全球权威的自然语言转SQL评测基准BIRD-Bench中， 九功模型凭借意图理解、推理分析与SQL生成能力获得了执行准确率（EX）与查询效率奖励（R- VES）双料冠军。认为九功模型能够斩获双榜冠军，彰显了朗新集团较强的AI技术实力，也为相关模型 在能源行业的落地打下良好基础。九功模型功能强大，赋能公司电力现货交易等新兴业务。随着香 港"稳定币+RWA"生态的发展，朗新有望凭借其较好的业务场景和先发优势，在绿色能源+区块链领域 成为重要的参与者和生态建设方，从而为自身业务发展和商业模式扩展提供助力。参照可比公司，认为 公司合理估值水平为2025年41倍市盈率，对应目标价为22.96元，维持"买入"评级。 ...

Core Viewpoint - Dongfang Securities report highlights that Ganli Pharmaceutical's innovative drug data is impressive, particularly the glucose-lowering effects of GZR18, indicating strong future growth potential for the company [1] Group 1: Drug Development and Clinical Data - Ganli Pharmaceutical has leading R&D expenditures in the industry, with multiple key products gradually disclosing Phase II clinical data since 2025 [1] - GZR18 (Bofang Glutide) shows superior glucose-lowering effects in Type 2 diabetes patients, with HbA1c and weight reductions exceeding those of the Semaglutide group after 24 weeks of biweekly injections [1] - After 23 weeks of treatment, GZR18 subjects experienced an average weight loss of 6.92 kg, representing a 9.3% reduction from baseline [1] - The Phase II clinical data for GZR4, an insulin weekly formulation, indicates good safety and a more significant reduction in HbA1c compared to daily insulin degludec (Novo Nordisk) in patients with poor baseline insulin control after 16 weeks of treatment [1] Group 2: Market Outlook and Valuation - The company anticipates a substantial 32.6% increase in the volume of its third-generation insulin agreements in the upcoming centralized procurement in 2024, alongside a rebound in product prices [1] - Leveraging the market coverage advantages gained from centralized procurement, the company's annual performance expectations are further solidified [1] - The company is assigned a 37x PE valuation for 2025, corresponding to a target price of 70.67 yuan, maintaining a "buy" rating [1]

Group 1 - The A-share private placement market has shown significant recovery this year, with 76 listed companies completing private placements by July 30, raising a total of 663.3 billion yuan, a year-on-year increase of 667.15% [1][3] - The active participation in the private placement market spans various industries, with capital goods, materials, and technology hardware and equipment leading in the number of listed companies involved [3] - Four major banks, including Bank of China and Postal Savings Bank, have raised over 100 billion yuan each through private placements, primarily for liquidity support [3] Group 2 - The growth in the private placement market has directly boosted the investment banking revenue for securities firms, with underwriting and advisory fees making up a significant portion of the issuance costs [4] - A total of 31 securities firms acted as lead underwriters for private placements, with CITIC Securities leading by underwriting 21 companies [4] - 62 out of the 76 companies that completed private placements disclosed their issuance costs, totaling 904 million yuan [4] Group 3 - Securities firms have actively participated in private placements, with 8 firms and 5 asset management companies involved in 25 companies, totaling 46 subscription instances [5] - Leading firms like GF Securities and Hua'an Asset Management have been prominent in participating in private placements, enhancing their returns and supporting the real economy [5] - The substantial subscriptions by top securities firms signal positive market sentiment, boosting investor confidence and market activity [5]

Group 1 - The A-share market has seen a significant increase in private placements, with 76 companies completing placements and raising a total of 663.3 billion yuan, a year-on-year increase of 667.15% [1][2] - The majority of companies involved in private placements are from the capital goods, materials, and technology hardware sectors, with 21, 10, and 9 companies respectively [2] - Four banks raised over 100 billion yuan each through private placements, aimed at supplementing liquidity, while the remaining companies raised less than 20 billion yuan for various purposes [2] Group 2 - Securities firms are capitalizing on the recovery of the private placement market, benefiting from increased underwriting fees and potential investment returns from subscribed shares [3] - The expansion of private placement business is expected to enhance the revenue of securities firms, with underwriting and advisory fees being a significant portion of the issuance costs [3][4] - A total of 31 securities firms acted as lead underwriters for private placements, with CITIC Securities leading by underwriting 21 companies [4] Group 3 - Securities firms' participation in private placements is seen as beneficial for both their own profitability and the support of the real economy and industry upgrades [5][6] - The large-scale subscriptions by leading securities firms send positive signals to the market, boosting investor confidence and trading activity [6]

Core Viewpoint - The report from Dongfang Securities highlights the growing focus of telecom operators on AI terminals, particularly in the smart home sector, which is expected to drive growth opportunities in the industry [1][2]. Group 1: Telecom Operators' AI Terminal Development - Leading telecom operators are continuously launching AI terminals such as mobile smart screens, showing impressive product growth [1]. - In March 2025, China Unicom and ZTE jointly released a series of innovative AI smart home terminal products, including smart screens and AI cameras [1]. - In May 2025, China Telecom upgraded its Tianyi AI central screen to serve as a comprehensive AI life assistant, indicating strong competitive advantages in the smart home business [1]. Group 2: Market Growth and Sales Data - The market for mobile smart screens, represented by China Mobile, is experiencing robust growth, with a projected retail volume of 254,000 units in 2024, reflecting a 65% year-on-year increase [2]. - The industry is expected to maintain rapid growth as telecom operators increase their investments in home AI terminals [2]. Group 3: AI Model Investments and Product Offerings - Telecom operators are investing heavily in AI models to enhance the intelligence of their terminals [3]. - China Mobile showcased its JiuTian Basic Model V3.0 at the 2025 World Artificial Intelligence Conference, while China Telecom introduced its self-developed Starry Sky Model system, enhancing the functionality of its terminal products [3]. - Future product promotions and subsidy policies from telecom operators are anticipated to improve the penetration of AI terminals in home settings [3].

Core Insights - Yongxin Optical is recognized as a national-level manufacturing champion and has entered a new phase of domestic substitution in high-end optical microscopes [1] - The high-end optical microscope market in China has significant potential but has been dominated by foreign companies for a long time [1] - The company has developed technical capabilities comparable to top global optical microscope manufacturers through OEM, industry-academia-research collaboration, and undertaking major national projects [1] Industry Summary - The high-end microscope segment has seen rapid growth, achieving over 5% domestic substitution and further increasing market share year-on-year [1] - In 2024, the company's microscope business revenue is expected to decline by 14% to 356 million yuan due to industry demand recovery and equipment update policies, raising concerns about the pace of domestic substitution [1] - Despite the overall revenue decline, high-end microscope revenue continues to grow [1] - The implementation of China's scientific instrument domestic substitution strategy and increasing uncertainty in the international trade environment are expected to accelerate breakthroughs in the company's optical microscope business [1] - Increased funding for equipment updates in 2025, with the first batch of funds already allocated and the second batch undergoing project review, is anticipated to expedite the procurement process for high-end microscopes [1] - The company's microscope business is projected to resume growth starting in 2025 [1] Valuation Summary - Based on comparable companies' 2025 price-to-earnings (PE) ratio of 44 times, the target price is set at 110.88 yuan, maintaining a "buy" rating [1]